Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017 (2017), Article ID 9606985, 7 pages
https://doi.org/10.1155/2017/9606985
Research Article

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

1Division of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, China
2Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China
3Department of Endocrinology, Kunshan Rehabilitation Hospital, Suzhou, Jiangsu 215314, China
4Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
5Shanghai Pituitary Tumor Center, Shanghai 200040, China
6Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China
7Department of Endocrinology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, China

Correspondence should be addressed to Zhaoyun Zhang; nc.ude.naduf@gnahznuyoahz

Received 28 November 2016; Accepted 23 January 2017; Published 15 March 2017

Academic Editor: Andrea G. Lania

Copyright © 2017 Wenjuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA). Our aim was to evaluate the value of the immunohistochemical (IHC) scores of 2 subtypes, SSTR2 and SSTR5, in predicting the short-term efficacy of SSA therapy in patients with active acromegaly. Ninety-three newly diagnosed acromegalic patients were included in our study. These patients were categorized into either a SSA-pretreated group (SA, ) or a direct-surgery group (DS, ), depending on whether or not presurgical SSA treatment was received. IHC analysis, using a 12-grade scoring system, with rabbit monoclonal antibodies against SSTR2 and SSTR5, was performed on all adenoma tissues. The reduction of GH, IGF-1, and tumor size after treatment with SSA for 3 months was measured. Compared with that in the DS group, SSTR2 expression was lower in the SA group. Additionally, in the SA group, SSTR2 expression was positively correlated with the reduction of IGF-1 and tumor volume. However, there was no correlation between the SSTR5 score and the efficacy of SSA. In conclusion, the protein expression of SSTR2, but not of SSTR5, is a valuable indicator in predicting biochemical and tumor size response to short-term SSA treatment in acromegalic patients.